Skip to main content
NCBI home page
Gut logoLink to Gut
. 1994;35(3 Suppl):S15–S19. doi: 10.1136/gut.35.3_suppl.s15

Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis.

M W Büchler 1, M Binder 1, H Friess 1
PMCID: PMC1374390  PMID: 7911442

Abstract

Acute pancreatitis is caused by the activation of digestive enzymes in the pancreas and a possible treatment, therefore, is the inhibition of enzyme secretion. This approach is somewhat controversial, however, as it is not clear whether pancreatic secretion continues to occur during the course of acute pancreatitis. Animal studies show an appreciable reduction of secretion in the inflamed pancreas, but studies in humans are not conclusive. The use of somatostatin or its analogue, octreotide, has been investigated in several clinical studies. A meta analysis of six individual studies in which somatostatin was given for acute pancreatitis showed that somatostatin significantly reduces mortality. A trial in patients with moderate to severe acute pancreatitis showed a lower rate (although not statistically significant) of complications in patients treated with 3 x 200 and 3 x 500 micrograms/day octreotide, compared with controls and patients receiving a lower dose of octreotide. A further study showed a significant reduction in patient controlled analgesics in patients treated with octreotide compared with controls. Pain is the important clinical symptom of chronic pancreatitis, possibly resulting from an increased intraductal pressure during secretion. The effect on pain of the inhibition of pancreatic secretion by octreotide has been investigated in two studies. One showed no significant reduction in pain after treatment with octreotide for three days. In the other, in which octreotide was used for three weeks, significantly less pain and analgesic use was recorded during octreotide treatment than during placebo. The most common complication of chronic pancreatitis is the formation of pseudocysts. There is some evidence that octreotide may be useful in their treatment.

Full text

PDF
S15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelini G., Pederzoli P., Caliari S., Fratton S., Brocco G., Marzoli G., Bovo P., Cavallini G., Scuro L. A. Long-term outcome of acute necrohemorrhagic pancreatitis. A 4-year follow-up. Digestion. 1984;30(3):131–137. doi: 10.1159/000199097. [DOI] [PubMed] [Google Scholar]
  2. Banks P. A. Predictors of severity in acute pancreatitis. Pancreas. 1991;6 (Suppl 1):S7–12. doi: 10.1097/00006676-199101001-00003. [DOI] [PubMed] [Google Scholar]
  3. Barkin J. S., Reiner D. K., Deutch E. Sandostatin for control of catheter drainage of pancreatic pseudocyst. Pancreas. 1991 Mar;6(2):245–248. doi: 10.1097/00006676-199103000-00019. [DOI] [PubMed] [Google Scholar]
  4. Baxter J. N., Imrie C. W., McKay C. J. Acute pancreatitis and octreotide. Lancet. 1991 Aug 10;338(8763):389–389. doi: 10.1016/0140-6736(91)90529-x. [DOI] [PubMed] [Google Scholar]
  5. Beger H. G., Bittner R., Block S., Büchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology. 1986 Aug;91(2):433–438. doi: 10.1016/0016-5085(86)90579-2. [DOI] [PubMed] [Google Scholar]
  6. Braganza J. M. Pancreatic disease: a casualty of hepatic "detoxification"? Lancet. 1983 Oct 29;2(8357):1000–1003. doi: 10.1016/s0140-6736(83)90983-2. [DOI] [PubMed] [Google Scholar]
  7. Broe P. J., Zinner M. J., Cameron J. L. A clinical trial of cimetidine in acute pancreatitis. Surg Gynecol Obstet. 1982 Jan;154(1):13–16. [PubMed] [Google Scholar]
  8. Büchler M., Friess H., Klempa I., Hermanek P., Sulkowski U., Becker H., Schafmayer A., Baca I., Lorenz D., Meister R. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg. 1992 Jan;163(1):125–131. doi: 10.1016/0002-9610(92)90264-r. [DOI] [PubMed] [Google Scholar]
  9. Büchler M., Malfertheiner P., Friess H., Isenmann R., Vanek E., Grimm H., Schlegel P., Friess T., Beger H. G. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology. 1992 Dec;103(6):1902–1908. doi: 10.1016/0016-5085(92)91450-i. [DOI] [PubMed] [Google Scholar]
  10. Büchler M., Malfertheiner P., Schädlich H., Nevalainen T. J., Friess H., Beger H. G. Role of phospholipase A2 in human acute pancreatitis. Gastroenterology. 1989 Dec;97(6):1521–1526. doi: 10.1016/0016-5085(89)90398-3. [DOI] [PubMed] [Google Scholar]
  11. Büchler M., Malfertheiner P., Uhl W., Schölmerich J., Stöckmann F., Adler G., Gaus W., Rolle K., Beger H. G. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993 Apr;104(4):1165–1170. doi: 10.1016/0016-5085(93)90288-n. [DOI] [PubMed] [Google Scholar]
  12. Büchler M. Objectification of the severity of acute pancreatitis. Hepatogastroenterology. 1991 Apr;38(2):101–108. [PubMed] [Google Scholar]
  13. Cameron J. L., Mehigan D., Zuidema G. D. Evaluation of atropine in acute pancreatitis. Surg Gynecol Obstet. 1979 Feb;148(2):206–208. [PubMed] [Google Scholar]
  14. Choi T. K., Mok F., Zhan W. H., Fan S. T., Lai E. C., Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut. 1989 Feb;30(2):223–227. doi: 10.1136/gut.30.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Czyzyk A., Szadkowski M., Muszyński J. Reduced inhibitory effect of somatostatin on the exocrine function of the pancreas and on serum insulin (IRI) levels in chronic relapsing pancreatitis. Horm Metab Res. 1984 Dec;16 (Suppl 1):155–159. doi: 10.1055/s-2007-1014922. [DOI] [PubMed] [Google Scholar]
  16. D'Amico D., Favia G., Biasiato R., Casaccia M., Falcone F., Fersini M., Marrano D., Napolitano F., Oliviero S., Rodolico A. The use of somatostatin in acute pancreatitis--results of a multicenter trial. Hepatogastroenterology. 1990 Feb;37(1):92–98. [PubMed] [Google Scholar]
  17. Evander A., Hederström E., Hultberg B., Ihse I. Exocrine pancreatic secretion in acute experimental pancreatitis. Digestion. 1982;24(3):159–167. doi: 10.1159/000198792. [DOI] [PubMed] [Google Scholar]
  18. Gislason H., Grønbech J. E., Søreide O. Pancreatic ascites: treatment by continuous somatostatin infusion. Am J Gastroenterol. 1991 Apr;86(4):519–521. [PubMed] [Google Scholar]
  19. Gjørup I., Roikjaer O., Andersen B., Burcharth F., Hovendal C., Pedersen S. A., Christiansen P., Wara P., Andersen J. C., Balslev I. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet. 1992 Nov;175(5):397–400. [PubMed] [Google Scholar]
  20. Goebell H., Ammann R., Herfarth C., Horn J., Hotz J., Knoblauch M., Schmid M., Jaeger M., Akovbiantz A., Linder E. A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol. 1979;14(7):881–889. doi: 10.3109/00365527909181420. [DOI] [PubMed] [Google Scholar]
  21. Gullo L., Barbara L. Treatment of pancreatic pseudocysts with octreotide. Lancet. 1991 Aug 31;338(8766):540–541. doi: 10.1016/0140-6736(91)91102-z. [DOI] [PubMed] [Google Scholar]
  22. Jenkins S. A., Baxter J. N., Day D. W., Al-Sumidaie A. M., Leinster S. J., Shields R. The effects of somatostatin and SMS 201-995 on experimentally-induced pancreatitis and endotoxaemia in rats and on monocyte activity in patients with cirrhosis and portal hypertension. Klin Wochenschr. 1986;64 (Suppl 7):100–106. [PubMed] [Google Scholar]
  23. Kwan D., Aufses A. H., Jr Short-term administration of SMS 201-995 in the management of an external pancreatic fistula. Am J Gastroenterol. 1989 Mar;84(3):326–328. [PubMed] [Google Scholar]
  24. Lankisch P. G., Koop H., Winckler K., Fölsch U. R., Creutzfeldt W. Somatostatin therapy of acute experimental pancreatitis. Gut. 1977 Sep;18(9):713–716. doi: 10.1136/gut.18.9.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Limberg B., Kommerell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med. 1980 Jul 31;303(5):284–284. doi: 10.1056/NEJM198007313030517. [DOI] [PubMed] [Google Scholar]
  26. Mazo A., Fujii Y., Shimotake J., Escribano M. J. Expression of fetoacinar pancreatic (FAP) protein in the pancreatic human tumor cell line BxPC-3. Pancreas. 1991 Jan;6(1):37–45. doi: 10.1097/00006676-199101000-00006. [DOI] [PubMed] [Google Scholar]
  27. Mitchell C. J., Playforth M. J., Kelleher J., McMahon M. J. Functional recovery of the exocrine pancreas after acute pancreatitis. Scand J Gastroenterol. 1983 Jan;18(1):5–8. doi: 10.3109/00365528309181549. [DOI] [PubMed] [Google Scholar]
  28. Niederau C., Niederau M., Lüthen R., Strohmeyer G., Ferrell L. D., Grendell J. H. Pancreatic exocrine secretion in acute experimental pancreatitis. Gastroenterology. 1990 Oct;99(4):1120–1127. doi: 10.1016/0016-5085(90)90633-c. [DOI] [PubMed] [Google Scholar]
  30. Regan P. T., Malagelada J. R., Go V. L., Wolf A. M., DiMagno E. P. A prospective study of the antisecretory and therapeutic effects of cimetidine and glucagon in human acute pancreatitis. Mayo Clin Proc. 1981 Aug;56(8):499–503. [PubMed] [Google Scholar]
  31. Sarles H. Definitions and classifications of pancreatitis. Pancreas. 1991 Jul;6(4):470–474. doi: 10.1097/00006676-199107000-00015. [DOI] [PubMed] [Google Scholar]
  32. Schlarman D. E., Beinfeld M. C., Andrus C., Kaminski D. L. Effects of somatostatin on acute canine experimental pancreatitis. Int J Pancreatol. 1987 Aug;2(4):247–255. doi: 10.1007/BF02788402. [DOI] [PubMed] [Google Scholar]
  33. Schwedes U., Althoff P. H., Klempa I., Leuschner U., Mothes L., Raptis S., Wdowinski J., Usadel K. H. Effect of somatostatin on bile-induced acute hemorrhagic pancreatitis in the dog. Horm Metab Res. 1979 Dec;11(12):655–661. doi: 10.1055/s-0028-1092793. [DOI] [PubMed] [Google Scholar]
  34. Steer M. L., Meldolesi J. Pathogenesis of acute pancreatitis. Annu Rev Med. 1988;39:95–105. doi: 10.1146/annurev.me.39.020188.000523. [DOI] [PubMed] [Google Scholar]
  35. Steinberg W. M., Schlesselman S. E. Treatment of acute pancreatitis. Comparison of animal and human studies. Gastroenterology. 1987 Dec;93(6):1420–1427. doi: 10.1016/0016-5085(87)90275-7. [DOI] [PubMed] [Google Scholar]
  36. Szabo S. Somatostatin stimulates clearance and hepatic uptake of colloidal carbon in the rat. Life Sci. 1983 Nov 14;33(20):1975–1980. doi: 10.1016/0024-3205(83)90735-x. [DOI] [PubMed] [Google Scholar]
  37. Szabo S., Usadel K. H. Cytoprotection - organoprotection by somatostatin: gastric and hepatic lesions. Experientia. 1982 Feb 15;38(2):254–256. doi: 10.1007/BF01945097. [DOI] [PubMed] [Google Scholar]
  38. Usadel K. H., Kessler H., Rohr G., Kusterer K., Palitzsch K. D., Schwedes U. Cytoprotective properties of somatostatins. Klin Wochenschr. 1986;64 (Suppl 7):59–63. [PubMed] [Google Scholar]
  39. Zhu Z. H., Holt S., el-Lbishi M. S., Grady T., Taylor T. V., Powers R. E. A somatostatin analogue is protective against retrograde bile salt-induced pancreatitis in the rat. Pancreas. 1991 Sep;6(5):609–613. doi: 10.1097/00006676-199109000-00016. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES